奥扎格雷钠联合腺苷钴胺及胰激肽原酶肠溶片治疗糖尿病周围神经病变的疗效观察

目的 观察奥扎格雷钠注射液联合腺苷钴胺及胰激肽原酶肠溶片治疗糖尿病周围神经病变(DNP)的临床疗效.方法 选择2008年9月至2010年9月我院收治的DNP患者72例,随机分为观察组和对照组,2组均给予腺苷钴胺肌内注射及胰激肽原酶肠溶片口服,观察组在此治疗基础上加用奥扎格雷钠注射液.结果 治疗1疗程后,观察组总有效率为91.7%(31/36),对照组为63.9%(23/36),观察组疗效优与对照组,2组总有效率比较差异有统计学意义(x2=7.6,P0.05);2组治疗后比较,观察组优于对照组,差异均有统计学意义(P<0.05).结论 奥扎格雷钠联合腺苷钴胺及怡开治疗DNP是一种安全有效的方法.

Effect of sodium ozagrel combined with cobamamide and pancreatic kininogenase on diabetic peripheral neuropathy

Objective To observe curative effect of sodium ozagrel combined with cobamamide and pancreatic kininogenase in patients with diabetic peripheral neuropathy (DNP). Methods Seventy-two diabetes patients with DNP in our hospital from September, 2008 to September, 2010 were randomly divided into observation group and control group. All patients were treated with cobamamide by intramuscular injection and pancreatic kininogenase taken orally. In the observation group sodium ozagrel injection were added to the treatment used in the control group. Results After one course of treatment, the total effective rate in the observation group was 91. 7% (31/36),which was better than the control group (63. 9% ,23/36) (x =7. 6, P<0. 05). Motor nerve conduction velocity of median nerve before and after treatment was (42.9 ± 1.9)m/s and(45. 9 ± 3. 0) m/s in the observation group, and (42. 2 ± 1. 7) m/s and (43. 1 ± 2. 1) m/s in the control group. Motor nerve conduction velocity of peroneal nerve before and after treatment was (34. 9 ± 3. 9) m/s and (46. 1 ±3.0)m/s in the observation group, ,and (35. 6 ±3.4)m/s and(36. 8 ±2. 5)m/s in the control group;Sensory nerve conduction velocity of median nerve was (41.2 ±3.2) m/s and (48. 5 ±4.0) m/s in the observation group,and (41. 5 ±3. 8)m/s and(42.4 ±3. 6) m/s in the control group, sensory nerve conduction velocity of peroneal nerve was(35.4 ±3. 4) m/s and(44. 8 ± 3. 2) m/s in the observation group, and (35. 9 ± 4.4) m/s and(37. 6 ± 3. 3) m/s in the control group. The difference of nerve conduction velocity before and after treatment in the observation group reached the statistical significance(P<0. 05), whereas not significant in the control group (P > 0. 05). After treatment, the nerve conduction velocity in the observation group significant better than those in the control group (P < 0. 05). Conclusion The treatments of sodium ozagrel combined with cobamamide and pancreatic kininogenase in diabetic peripheral neuropathy is safe and effective.